子宫移植:当前评估、监测与新兴诊断技术
本文综述子宫移植(UTx)在术前评估、围手术期管理、移植后与妊娠监测及长期随访各阶段的评估与监测要点,并借鉴实体器官移植经验,探讨分子与等位基因水平HLA配型、免疫抑制最小化策略及供体来源游离DNA和血液尿液转录组等无创排斥监测工具的发展方向。
要点
- UTx正从实验阶段向临床常规过渡,方案与诊断标准化日益重要。
- 围手术期需关注急性外科处理、免疫抑制启动及早期移植物评估。
- 新兴无创排斥监测工具如供体来源游离DNA和转录组学有望改善结局。
核心结论
- 随着UTx向常规临床实践过渡,方案与诊断的标准化至关重要。
- 新兴分子诊断与无创监测工具有望改善移植物结局和患者照护。
研究设计与样本
- 本文为综述,描述UTx各主要照护阶段的当前评估、监测与新兴诊断,并借鉴广泛实体器官移植经验探讨未来方向。
主要发现
- 术前评估包括生育力评估与体外受精、外科、心理社会及供者评估,以及供受体匹配考虑。
- 围手术期管理聚焦急性外科照护、免疫抑制启动和早期移植物评估。
- 移植后与妊娠监测涵盖持续免疫抑制评估、活检判读、急性排斥管理及妊娠与母体并发症的检测与管理。
- 长期随访涉及再次妊娠可能及计划性移植物子宫切除以助免疫抑制撤除。
- 未来方向包括分子与等位基因水平HLA配型、免疫抑制最小化策略及无创排斥监测工具开发。
临床怎么用
- 临床应关注UTx各阶段评估与监测的标准化,并探索分子配型与无创监测工具的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Uterus transplantation (UTx) is uniquely positioned at the transition from experimental to clinical reality for women with absolute uterine factor insufficiency. As the technique gains wider clinical adoption, there is a growing need for standardization in both protocols and diagnostics. CONTENT: This review describes the current evaluation, monitoring, and emerging diagnostics in UTx across the main phases of care: (a) preoperative evaluation, which includes fertility evaluation and in vitro fertilization, surgical, psychosocial, and donor assessments, as well as donor-recipient matching considerations; (b) perioperative management, which focuses on acute surgical care, initiation of immunosuppression, and early graft evaluation; (c) posttransplant and pregnancy monitoring, which encompasses ongoing immunosuppression evaluation, biopsy interpretation, management of acute rejection, and detection and management of pregnancy and maternal complications; and (d) long-term follow-up, which addresses the potential for repeat pregnancies and planned graft hysterectomy to facilitate immunosuppression withdrawal.The review further explores future directions for clinical diagnostics in UTx, drawing on broader solid organ transplantation experiences. This includes molecular and allele-level human leukocyte antigen matching for recipient-donor compatibility, strategies for immunosuppression minimization, and the development of noninvasive rejection monitoring tools such as donor-derived cell-free DNA and novel blood and urine transcriptomics approaches. SUMMARY: Standardization of protocols and diagnostics is essential as UTx transitions to routine clinical practice. Emerging molecular diagnostics and noninvasive monitoring tools hold promise for improving graft outcomes and patient care in this evolving field.
引用
- Jacques A, Testa G, Mangiola M, et al. Uterus Transplantation-Current Evaluation, Monitoring, and Emerging Diagnostics. Clin Chem. 2025. PMID: 41468146. doi:10.1093/clinchem/hvaf143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。